Managing Partners

Edward Dow, M.D.

Edward Dow is a highly experienced Physician Executive/Hematologist-Oncologist with expertise in Global and USA Medical Affairs as well as Clinical Development providing data generation and synthesis for medical support of new product commercialization

Starting at Millennium Takeda, Ed was the lead for US Medical Affairs on Velcade, the perennial blockbuster drug for multiple myeloma, and then later at Baxalta-Shire, he was the Global Med Affairs Launch Lead for Vonvendi, the first-ever recombinant therapy for Von Willebrand Disease. In both roles, he was extremely versatile providing medical leadership and support for MSL teams, Commercial/Market Access, Health Economics and Outcomes Research, Payer Relations, as well as Health Policy, Government Affairs, and Patient Advocacy.

At Foundation Medicine Inc., he helped create a Medical Affairs Team to aid in clinical adoption and reimbursement of genomic profiling in routine clinical practice leading up to CMS recognition of Foundation One, and Foundation One Heme.

In addition, he develops and runs First In Human Clinical Trials for cancer immunotherapies and sickle cell anemia. A lifelong resident of Boston, he attended Harvard College and the Tufts Medical School before sub-specialty training in Hematology-Oncology at Tufts Medical Center, Massachusetts General Hospital including special training in bone marrow transplantation at Fred Hutchinson Cancer Research Center, Seattle, WA.

With over twenty years of full-time patient care experience, he continues to practice seeing patients with cancer and blood diseases on a part-time basis in a community setting - dealing very much on the front-lines with issues patients face with access to state of the art medicines and therapy.

Mobile: 617-877-4386

Office/Fax: 617-690-2161 | Edward.Dow@ValueGenome.com

Edward Dow is on Linkedin at www.linkedin.com/in/edward-dow-med

Jennifer King, MBA

Jennifer King is a Partner at Value Genome. She brings a wealth of commercial and access experience across oncology and orphan drugs. She has worked in Global, EMEA and Asia Pacific/Japan markets in Pricing & Market Access. She plays an active role in advising clients on pricing and market access strategies with the goal of achieving optimal access for all stakeholders. Her extensive industry experience across therapeutic areas and geographies ensures clients benefits from that knowledge in both strategic development and implementation.

In her last position, Jennifer was Head of Pricing & Market Access at Celgene where she led the successful reimbursement of all Celgene products in the Asia Pacific Region including Japan. She also led the Global launch of Abraxane in mBC and NSCLC as the Head of Market Access for Solid Tumor. Jennifer has over 20 years of pricing and market access experience and worked for Amgen, Pfizer and Merck prior to Celgene.

Jennifer has a B.A. in Biochemistry from University of California, Berkeley and a MBA from Lehigh University.

(1) 908-451-8242 | Jennifer.King@ValueGenome.com

Jennifer King is on Linkedin at www.linkedin.com/in/jennifer-t-king

Kevin Walker Mayo, PH.D., EJ.D.

Kevin Mayo is Managing Partner of Value Genome LLC.

Earlier in his career Kevin gained industry and consulting expertise in senior leadership roles with Value Genome, Baxalta, The Access Partnership, Endo Health Solutions, Bridgehead International, Daiichi Sankyo, Novartis Pharma AG, Pharmacia Corporation, AstraZeneca and Jazz.

Kevin completed a Master’s degree in Neuropsychology and a Doctoral degree in Pharmaceutical Marketing and Administration. More recently Kevin augmented his business education by completing an Executive Juris Doctorate in Health Law and Policy. He has served on the adjunct faculties for the Mayes College of Healthcare Business and Policy (University of the Sciences) and the College of Population Health (Thomas Jefferson University) and is a frequent presenter at international market access conferences. Kevin received a Distinguish Service Award from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for his contribution to the society.

(1) 781-752-9804 | Kevin.Mayo@ValueGenome.com

Kevin Mayo is on Linkedin at www.linkedin.com/in/kevinmayomarketaccess

Rob Philo, SVP and U.S. Practice Lead with Value Genome

Rob has built and led U.S. Market Access, Government, and Commercial teams and has over 20 years of Pricing and Market Access experience with an emphasis on rare/orphan drugs, drug dependence and organ transplant.

In the recent 15 years in the U.S. his areas of emphasis have been:

Rob has launched 4 different brands into the marketplace and has a broad range of success with product launch pricing and access strategies through the following experiences:

-20 years' experience Private payers with National MCOs and GPOs.

-Medicaid strategies for all 50 States, FFS and Managed with an expertise in supplemental rebates and pool bidding.

-Medicare A/B and D contracting and oversight with an emphasis on reimbursement and Inflation Reduction Act.

-340B, and Prime Vendor contracting.

-Hospital systems, inpatient and outpatient pharmacies.

-Specialty pharmacies network design.

-Hub and patient support design.

Internal C-Suite planning with gross to net and ROI assessments.

Rob has 20+ years of expertise with aligning Market Access objectives with corporate objectives in Sales, Sales Training and Marketing.

Rob has a B.A. in Communications from the University of Tennessee.

(1) 678-628-6210 | Rob.Philo@valuegenome.com

Rob Philo is on Linkedin at www.linkedin.com/in/robphilo

Bruce Wang, Ph.D.

Dr. Bruce Wang, PhD is a seasoned expert in Health Economics and Outcomes Research (HEOR) and Real-World Evidence. In his current roles, he serves as the head of the HEOR and Real-World Evidence practice at Value Genome. He is also Managing Director at Elysia Group, Ltd, a strategic partner renowned for its service excellence across the Asia-Pacific region.

With extensive expertise in modeling and database analysis, Bruce's career has been distinguished by his dedication for health economics. His work has included the implementation of several models and database studies that have influenced decision-makers on the reimbursement of pharmaceuticals and medical devices. His areas of expertise span a wide spectrum of healthcare, encompassing critical fields such as asthma, obesity, oncology, rare diseases, and cardiovascular disease.

Bruce is a prolific contributor to scholarly literature, actively publishing abstracts and papers in international journals. His commitment to knowledge dissemination has enriched the global healthcare community, driving evidence-based decision-making. Bruce's academic contributions extend beyond his research; he has served as an Affiliated Faculty at the University of Washington, where he has shared his wisdom and mentored the next generation of healthcare researchers.

Bruce's career has been a journey marked by transformative leadership. Prior to his current roles, he founded the HEOR group at Alliance Life Sciences (now Eversana) as Vice President. He also co-founded Elysia Group US, which was acquired by Real Chemistry where he served as Practice Leader. His global perspective was further refined during his tenure as a Visiting Senior Fellow at Taipei Medical University in Taiwan and as a Senior Fellow in the Pharmaceutical Outcomes Research & Policy Program at the University of Washington. He has also leveraged his expertise as an Economic Strategist at Goldman Sachs in New York. Bruce holds a Ph.D. in Economics from the University of Washington and a B.A. in Economics from Columbia University in New York. His relentless pursuit of excellence, visionary leadership, and commitment to advancing healthcare through evidence-based decision-making continue to shape the industry, ensuring that patients receive the best possible care and stakeholders make informed choices in a complex and dynamic healthcare landscape.

Bruce.Wang@valuegenome.com

Bruce Wang is on LinkedIn at www.linedin.com/in/bruce-wang-4b67bb50

Practice Leads

Joseph Rubino - Medical Technology Practice Lead

Joseph Rubino is a veteran market access, reimbursement and government affairs expert with interests in diagnostic and medical device strategy, HEOR and payer/provider market research. He leads Value Genome's projects focused upon coding, coverage, payment, evidence generation, launch plans and value communication strategies.

(1) 609-306-9102 | Joseph.Rubino@valuegenome.com

Joseph Rubino is on Linkedin at www.linkedin.com/in/jospeh-rubino-597bb6a

Geoffroy “Jeff” Coteur - Strategic Partner & EU Practice Lead

Jeff is a seasoned professional in the healthcare industry with a wealth of experience across market access, pricing, health economics & outcomes research, and real-world evidence strategies at Global and Regional-EU level. He has held leadership positions at pharmaceutical companies ranging from small biotech to F100 companies. Jeff has a passion for combining the science, the patients needs and the business opportunities. Prior to founding iPATH Solutions™ and joining Value Genome as Strategic Partner – EU Practice Lead, Jeff was the market access leader for infectious diseases & vaccines at Janssen Pharmaceutica where he shaped the commercial strategy of early assets and business development opportunities against viral and bacterial infections. During his tenure at Galapagos, Jeff led the market access & pricing function for the rare disease franchise in pulmonary fibrosis. He also designed the price management governance & systems in preparation of the first commercial launch of a drug for auto-immune diseases. Jeff started his career at UCB where he shaped the market access & pricing strategy of several biologics for auto-immune and bone disorders at Global level and has launched those products across EU countries.

+32.498.498.888 | Geoffroy.Coteur@valuegenome.com

Geoffroy “Jeff” Coteur is on LinkedIn at www.linkedin.com/in/Geoffroy-Coteur

Diana Steinway - Strategic Partner & Value Communications Practice Lead

Diana is Managing Director of APPA, with over 20 years of experience in the pharmaceutical industry. She started her career in the UK as a medical writer for licensed products, developing medical communications and running congress events for major brands in oncology and hematology, including Herceptin, Arimidex, Sutent and MabThera.

She started consulting in market access over 10 years ago, focusing on value communications and strategic solutions for complex market access situations. She specializes in value proposition development, value dossiers, landscape and therapy area assessments, and objection handling. As a consultant, she has collaborated with key opinion leaders, health economists, and market specialists to develop innovative market access solutions for a wide range of known therapeutics in key areas such as oncology and neurology, as well as for high-cost gene and cell therapies in rare diseases for which clinical and economic data are lacking. She has extensive expertise in European market access requirements and a keen understanding of the complexities of the US healthcare system, including alternative financing and contracting options such as outcomes-based agreements, annuities, and warranties.

+32.467.300.161 | Diana.Steinway@valuegenome.com

Diana Steinway is on Linkedin at www.linkedin.com/in/dianasteinway

Art Vrecenak - Strategic Partner & Payer Marketing Practice Lead

Principal at Access Acumen, Art has board experience across field sales, health economics, product management, clinical development, hospital/GPO marketing, national HMO marketing, national PBM marketing, strategic customer marketing, and generic product business strategy. He developed and lead teams tasked with value proposition development and communication for both pharma benefit and medical benefit products. This depth and breadth of experience feeds a passion for optimizing product performance throughout the product life cycle.

(1) 484-653-7921

Art Vrecenak is on LinkedIn at www.linkedin.com/in/accessaccumenllc

Stephen F. Amato, Ph.D., MBA – Strategic Partner & Global Regulatory Practice Lead

Steve is a global regulatory affairs expert with vast experience in the healthcare sector. With a strategically oriented, collaborative and evidence-based approach, he has worked directly with the FDA and developed strategies for medical device and biopharmaceutical products. Steve is principal advisor and Chief Strategist at tJun17 Life Science Advisors and serves as Department Chair and Professor of Regulatory Affairs and Quality Assurance at Northeastern University College of Professional Studies.

Stephen F. Amato is on LinkedIn at www.linkedin.com/in/steveamato

Who We Are

Value Genome, LLC. is a team of pharmaceutical and biotech executives with extensive real-world industry experience who share a common passion for assisting biopharmaceutical innovators in maximizing the pricing and reimbursement potential of their assets. We combine our health economic, medical, pricing, and reimbursement expertise with our extensive payer relations and direct product launch experience.

We collaborate with you in developing market access strategies by looking at the clinical development program through product launch and across your product life-cycle to reveal the CLINICAL and ECONOMIC VALUE of your asset as defined by key stakeholders.
We achieve this by engaging external stakeholders at all levels of health care delivery:

Government/Commercial Payers and Their Advisors
Physicians and Their Professional Societies
Healthcare and Insurance Networks
Patients and Patient Advocacy Organizations
Hospital and Treatment Centers
Health Technology Assessment Agencies
Ministry Officials
Health Economic Thought Leaders

The goal is to shape your clinical development program to be payer ready and to optimize your product access globally.

Strategic Collaborators and Advisors

Rapid Commercialization Partners, Inc. (RCP) is dedicated to accelerating commercial readiness for clinical-stage biotech companies and offers a foundational shift in how biotech companies can achieve commercial success and rapid time to value. Engaging a team of senior commercial leaders with comprehensive biotech experience and unparalleled proficiency in critical subject matter areas essential to support commercialization, RCP works provides strategic and executional expertise on critical decision points early in the commercialization process to build the commercial foundation, address observable inefficiency, and bring needed therapies to patients faster and with improved fiscal responsibility.

Joseph Eichenholz, MA

Chief US Value and Access Strategy Lead

https://linkedin.com/in/jospeh-eichenholz-7a025115/

Mark Rubino, R.Ph, M.B.A.

Retired, Former Chief Pharmacy Officer Value Genome LLC

https://linkedin/in/markrubino

You are a young life sciences company that has embarked on a demanding entrepreneurial journey. At your fingertips, you hold a promise of a technology that can help patients live better lives. But how do you turn your idea into a fully-fledged solution that physicians will prescribe, patients will use and payers will pay for, a product that has a realistic chance of being adopted in clinical practice?

If you are in such a position but lack the expertise or time to handle all that needs to be done, talk to me to explore how I can help you define or sharpen your business, portfolio or product strategy, and put fundamentals in place for a successful launch.

Pretium Strategy’s expertise includes:

Leading early commercial assessment and pipeline optimization
Shaping integrated development and commercialization strategies for new product launches
Driving cross-functional launch efforts to ensure seamless execution
Planning and executing global expansion, with a specialized focus on Europe
Scaling growth-stage companies for commercial launch

Pharma, Biotech, Medical Devices, Diagnostics, Digital Health

We enable life sciences companies to develop strategic commercialisation, access and pricing plans in the Middle East and Africa

The complexities of emerging markets such as the Middle East and Africa make launching and market access increasingly challenging. From a lack of market transparency, to limited data availability and competitive information, the challenges are endless.

Our strategic consultancy and unparalleled regional experience helps companies navigate these circumstances, identify optimal market access and pricing routes and deliver data-driven solutions to address even the most complex of challenges.

Managing Partners

Practice Leads

Who We Are

Strategic Collaborators and Advisors

Speak With Our Pharmaceutical Executives

Contact Us